期刊文献+

VEGF及其受体在恶性血液细胞系HL-60及Raji的表达 被引量:3

The Expression of Vascular Endothelial Growth Factor and Its Receptor in Hematopoietic Malignant Cell Lines HL-60 and Raji
在线阅读 下载PDF
导出
摘要 为了探讨血管内皮生长因子 (VEGF)在恶性血液病中的作用 ,以恶性血液细胞系HL 6 0和Raji为实验对象 ,应用RT PCR及ELISA法检测肿瘤细胞。VEGF基因的表达 ,并采用免疫组织化学染色法测定细胞表面VEGF受体Flt 1的表达。结果显示 :髓性白血病细胞系HL 6 0和淋巴瘤细胞系Raji中均存在VEGF mRNA的表达。在培养 4 8小时后 ,HL 6 0细胞和Raji细胞的培养上清液中VEGF含量明显高于正常人外周血单个核细胞。VEGF R(Flt 1)在两种肿瘤细胞的胞膜上均有表达 ,而正常人外周血单个核细胞上无表达。这一结果表明 ,白血病和淋巴瘤细胞具有产生VEGF的能力 ,并可将VEGF分泌到细胞外基质微环境中。VEGF可作用于白血病和淋巴瘤细胞本身 ,在恶性血液肿瘤细胞中存有VEGF的自分泌途径 ,而VEGF的自分泌成为血液肿瘤细胞高侵袭性生物学特性的基础。结论 :抑制VEGF的分泌将有助于阻断其与内皮细胞间的互动环 ,降低其增殖、抗凋亡和侵袭性能 。 In order to explore the effect of vascular endothelial growth factor (VEGF) in hematological malignancies, the expression of VEGF and its receptor was detected in HL 60 and Raji cells by reverse transcriptase polymerase chain reaction (RT PCR), enzyme linked immunosorbent assay (ELISA) and immunohistochemistry. The results showed that VEGF mRNA expressed in both HL 60 and Raji cells, and the mean VEGF concentrations in the cultural supernatant of both cell lines were significantly higher than that of normal peripheral blood mononuclear cell respectively. There was expression of VEGF R (Flt 1) on the surfaces of both HL 60 and Raji cells. The research results demonstrated that VEGF mRNA was expressed in hematopoietic malignant cell lines (HL 60 and Raji), and the corresponding protein was secreted into the extracellular microenvironment, the both cell lines expressed VEGF R on the cell surface. VEGF affects not only vascular endothelial cells, but also leukemic and lymphoma cells themselves. It is suggested that an autocrine pathway of VEGF existed in the both cell lines other than the paracrine pathway. The autocrine pathway of VEGF works as basis of tumor invasion. In conclusion, to restrain expression of VEGF and its receptor may inhibit tumor growth, and helps to block the reciprocal loop between VEGF and endothelial cells, and decrease the tumor specialities of hyperproliferation, anti apoptosis and invation, that may make the tumor more susceptibile to chemotherapy.
出处 《中国实验血液学杂志》 CAS CSCD 2003年第4期376-380,共5页 Journal of Experimental Hematology
关键词 血管内皮生长因 恶性血液细胞系 HL-60细胞 RAJI细胞 vascular endothelial growth factor hematopoietic malignant cell line HL 60 cell Raji cell
  • 相关文献

参考文献19

  • 1阮国瑞,刘艳荣,陈珊珊,秦亚溱,于弘,常艳,李金兰,付家瑜.自分泌VEGF对人慢性髓性白血病细胞系K562的作用[J].中国实验血液学杂志,2001,9(3):202-206. 被引量:10
  • 2Folkman J. Tumor angiogenesis: therapeutic implications. New Engl J Med, 1971; 285:1182- 1186.
  • 3Cohen T, Nahari D, Cerem LW, et al. lnterleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem,1996; 271:736 - 741.
  • 4Weidner N, Semple JP, Welch WR, et al. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med,1991; 324:1-8.
  • 5Ohta Y, Endo Y, Tanaka, et al. Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer. Clin Cancer Res, 1996; 2:1411- 1416.
  • 6Joseph IB, Nelson JB, Denmeade SR, et al. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Cancer Res, 1997; 3:2507- 2511.
  • 7Weidner N, Carroll PR, Flax J, et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol,1993; 143:401 - 409.
  • 8Perez-Atayde AR, Sallan SE, Tedrow U, et al. Spectrum of tumor angiogenesis in the bone marrow of children with acute lympboblasticleukemia. Am J Pathol, 1997; 150:815- 821.
  • 9Fiedler W, Graeven U, Ergun S, et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood, 1997; 89:1870 - 1875.
  • 10Aguayo A, Estey E, Kantarjian H, et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood, 1999; 94:3717- 3721.

二级参考文献3

共引文献9

同被引文献33

  • 1王一,肖志坚,刘澎,彭智,韩忠朝.急性髓系白血病血管新生因子的表达及临床意义[J].癌症,2004,23(z1):1423-1427. 被引量:3
  • 2费嘉,张洹.VEGF反义核酸对HL-60细胞作用和机制研究[J].中国实验血液学杂志,2004,12(5):640-643. 被引量:3
  • 3黄慧强,卜庆,黄欣,周中梅.沙利度胺单药治疗三例耐药滤泡型淋巴瘤患者[J].中华血液学杂志,2006,27(10):704-705. 被引量:5
  • 4Bosma GC, Custer RP, Bosma MJ. A severe combined immuno-deficiency mutation in the mouse. Nature, 1983; 301 : 527 -530.
  • 5Yang ZF, Poon RT, Liu Y, et al. High doses of tyrosine kinase inhibitor PTK787 enhance the efficacy of ischemic hypoxia for the treat- ment of hepatocellular carcinoma : dual effects on cancer cell and angiogenesis . Mol Cancer Ther, 2006 ; 5 : 2261 - 2270.
  • 6Yazici YD, Kim S, Jasser SA, et al. Antivascular therapy of oral tongue squamous cell carcinoma with PTK787. Laryngoscope, 2005 ; 115 : 2249 -2255.
  • 7Bellamy WT, Richter L, Sirjani D, et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood, 2001 ; 97 : 1427 - 1434.
  • 8Padro T, Bieker R, Ruiz S, et al. Overexpression of vascular endo- thelial growth factor(VEGF) and its cetular receptor KDR( VEGFR-2 ) in the bone marrow of patients with acute myeloid leukemia. Leukemia, 2002; 16:1302 - 1310.
  • 9Dias S, Hattori K, Zhu Z, et al. Autocrine stimulation of VEGFR-2 activates human leukemia cell growth and migration. J Clin Invest, 2000; 106:511 -521.
  • 10Katoh O, Takahashi T, Oguri T, et al. Vascular endothelial growth factor inhibits apopotic death in hematopoietic cell after exposure to chemotherapeutic drugs by inducing MCL-1 acting as an antiapoptotic factor. Cancer Res, 1998; 58:5565-5569.

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部